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CASE PRESENTATION
A 67-year-old black man presented with a 7-year his-
tory of hypertension. He smoked 2 packs of cigarettes
per day for 20 years but quit completely after a stroke 4
years ago. He was employed as a maintenance man, and
his annual household income was less than $14,000. The
patient had been treated intermittently with antihyper-
tensive agents, but follow-up had not been consistent,
and scant records of blood pressure recordings indicated
inadequate control (>140/>80 mm Hg). After the stroke
4 years ago, he was hospitalized with right-sided hemi-
paresis that resolved completely. He had been treated
intermittently for gout with colchicine and nonsteroidal
anti-inflammatory drugs. His medications at presenta-
tion were atenolol, 100 mg/day; hydrochlorothiazide,
25 mg/day; and triamterene, 10 mg/day. He was advised
to adhere to a low-salt diet but admitted that he did not
comply.
The family history was significant. The patient’s father
died of a stroke while on maintenance hemodialysis; his
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end-stage renal disease (ESRD) was attributed to hyper-
tension. The patient’s mother was alive and had type 2
diabetes, hypertension, and a history of myocardial in-
farction. He had two sisters and one brother. One sis-
ter and one brother were hypertensive, but neither
was known to have target organ damage. The patient’s
45-year-old son has hypertension and takes antihyper-
tensive medication.
At presentation, the patient’s blood pressure was
210/130 mm Hg; pulse rate, 68 beats/min; height, 1.8 m
(5 feet, 10 inches); weight, 90 kg (198 pounds). He had
grade 2 hypertensive retinopathy, an S4 gallop, and pit-
ting pretibial edema. No tophi were present, and his neu-
rologic examination was normal. An electrocardiogram
revealed left-ventricular hypertrophy. Fasting laboratory
data included: blood urea nitrogen (BUN), 28 mg/dL;
serum creatinine, 2.4 mg/dL; sodium, 140 mEq/L; potas-
sium, 4.6 mEq/L; chloride, 104 mEq/L; total CO2,
23 mmol/L; calcium, 9.2 mg/dL; phosphorus, 4.3 mg/dL;
albumin, 4.2 g/dL; total cholesterol, 238 mg/dL; low-
density lipoprotein (LDL) cholesterol, 155 mg/dL;
triglyceride, 202 mg/dL; uric acid, 8.1 mg/dL; aspar-
tate aminotransferase (AST), 23 IU; alanine aminotrans-
ferase (ALT), 30 IU; alkaline phosphatase, 110 IU; and
total bilirubin, 1.0 mg/dL. A complete blood count re-
vealed 5800 white blood cells/mm3; hemoglobin, 14.3 g/
dL; packed red blood cells, 41%; and a normal platelet
count. Hepatitis serologies, including HBsAg and HCV
RNA, were negative. Urinalysis revealed a specific grav-
ity of 1.021; pH, 5.0; 1+ protein; and no abnormal cells,
casts, or crystals. A 24-hour urine collection contained
1.65 g creatinine; protein, 1056 mg; and sodium, 269 mEq.
Serum protein electrophoresis was normal, and urinary
protein electrophoresis disclosed nonselective protein-
uria. Glomerular filtration rate (GFR), estimated by io-
thalamate clearance, was 55 mL/min/1.73 m2.
The patient was treated with atenolol, 100 mg once
daily; furosemide, 40 mg twice daily; and verapamil,
240 mg twice daily. He was followed closely at intervals
of 1 to 3 months and subsequently every 3 to 6 months.
Antihypertensive medication was titrated frequently to
maintain his blood pressure in the range of 130–140 mm
Hg systolic and 80–85 mm Hg diastolic. During the first
24 months of follow-up, his serum creatinine remained
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Fig. 1. Clinical course of patient with biopsy-proven hypertensive
nephrosclerosis.
relatively stable in the range of 2.5 to 2.8 mg/dL (Fig. 1).
His average blood pressure during this period was 128/81
mm Hg. Despite continued blood pressure control in
the range of 110–140/75–85 mm Hg, his serum creatinine
gradually increased. At a clinic visit 36 months after ini-
tial evaluation, his serum creatinine was 3.1 mg/dL, and
the 24-hour urinary protein excretion had increased to
1.5 g. No change in treatment was recommended. At a
clinic visit 48 months after initial presentation, physical
examination revealed a blood pressure of 130/80 mm Hg;
an S4 gallop; and trace pretibial edema. The serum cre-
atinine was 4.1 mg/dL; 24-hour urine protein, 3.0 g; and
urinary sodium, 196 mEq/day. Serum and urine protein
electrophoreses were unrevealing.
A renal biopsy was performed. Light microscopy dis-
closed arteriolar sclerosis and hyalinosis, global and
focal glomerular sclerosis, and evidence of glomerular
ischemia (simplification). Also present were interstitial
fibrosis with tubular atrophy and chronic interstitial in-
flammation, findings consistent with the diagnosis of
hypertensive nephrosclerosis. Immunofluorescence and
electron microscopy revealed findings consistent with
hypertensive nephrosclerosis. The patient’s medications
were not changed. Despite continued adequate blood
pressure control, his renal function continued to dete-
riorate, and hemodialysis was initiated 72 months after
his initial visit.
DISCUSSION
Dr. Robert D. Toto (Professor of Medicine, Uni-
versity of Texas Southwestern Medical Center, Dallas,
Texas, USA): Hypertensive nephrosclerosis is an im-
portant public health problem. A heterogeneous
disease, its pathogenesis and pathophysiology are
incompletely understood. On average, the rate of
progression is relatively slow as compared with di-
abetic nephropathy, some glomerulonephritides, and
autosomal-dominant polycystic kidney disease. Treat-
ment includes pharmacologic lowering of blood pressure
with an angiotensin-converting enzyme (ACE) inhibitor,
whenever possible. Additional modifiable risk factors be-
yond blood pressure control and inhibition of the renin-
angiotensin-aldosterone system are important in patient
management. Last, future studies are needed to improve
detection, diagnosis, and treatment. Let’s look at each of
these key points in turn.
Epidemiology
Approximately 6% of patients with essential hyper-
tension have chronic kidney disease and are at risk for
progression to ESRD [1]. Hypertension is cited as the
cause of ESRD in approximately 30% of new cases in
the United States [2] and is the second leading cause of
ESRD in African Americans. The incidence of hyperten-
sive nephrosclerosis is increasing; however, the rate of
increase has decreased somewhat in the past 5 years [2].
The reason for this rate decrease is not clear, but it might
represent reclassification of hypertensive nephrosclerosis
as diabetic nephropathy or other renal disease. Moreover,
the incidence of ESRD attributed to hypertension is five-
fold higher in African Americans than in non-African
Americans [2–4]. The health care costs for managing
ESRD attributed just to hypertension exceed $1 billion
annually.
In general, hypertension in African Americans devel-
ops at an earlier age, is more severe, and is more difficult
to control. Thus it is not surprising that ESRD attributed
to hypertension generally occurs at a younger age in
African Americans as compared to non-African Amer-
icans [2]. Epidemiologic and case-control studies have
demonstrated increased risk for hypertension as a cause
of ESRD in the United States [5–13] and in Australian
aborigines [14]. Factors that might account for racial dis-
parity in ESRD attributed to hypertension include a lack
of access to medical care, socioeconomic status [7, 15–18],
severity and duration of hypertension [1, 19–22], educa-
tion level [7, 22, 23], alcohol and drug abuse [24, 25],
genetic predisposition [26–31], and nephron endowment
[32–37]. The National Health and Nutrition Examination
Survey II indicates that modifiable risk factors, includ-
ing sociodemographic, lifestyle, and clinical factors, “ex-
plain” less than one-half of the increased risk for ESRD in
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Table 1. Risk factors for hypertensive nephrosclerosis
Age (older than 50 years)
Male gender
African American race
Systolic hypertension
Dyslipidemia
Family history
Duration of hypertension
Severity of hypertension
Proteinuria
Decreased glomerular filtration rate
Low socioeconomic status
Decreased nephron number
Cigarette smoking
African Americans [22, 38, 39]. In this analysis, the unad-
justed relative risk of ESRD among African Americans
was 2.96 and after adjustment for these factors decreased
to 1.96 but remained significant. Therefore, other risk fac-
tors, including genetic determinants, likely play an impor-
tant role in predisposing African Americans to ESRD.
Risk factors
Numerous risk factors influence the onset and progres-
sion of hypertensive nephrosclerosis (Table 1). Today’s
patient had most of these. He was an older black male
with longstanding hypertension, a family history of renal
disease, low socioeconomic status, a history of cigarette
smoking, severe systolic hypertension, advanced chronic
renal disease, and dyslipidemia.
Systolic hypertension is a powerful predictor of the
development of ESRD [40]. Analysis of the impact of
systolic hypertension among 334,000 men screened for
the Multiple Risk Factor Intervention Trial (MRFIT) in-
dicated that systolic hypertension was an independent
risk factor for all-cause ESRD. Moreover, the relation-
ship between systolic blood pressure and the develop-
ment of ESRD was graded and consistent throughout the
range of blood pressures recorded at the time of screening
into the study [41]. In addition to data from MRFIT, the
Atherosclerosis Risk in Communities (ARIC) observa-
tional study [23], the Hypertension Detection and Follow-
Up Program (HDFP) [1], the Systolic Hypertension in
the Elderly Program (SHEP), and the VA Cooperative
Trial report that systolic blood pressure is an indepen-
dent risk factor for ESRD attributed to hypertension [21,
40, 42]. Systolic hypertension has been overlooked as a
major risk factor for renal and cardiovascular outcomes
in hypertensive populations [43]. With the exception of
studies specifically focused on systolic hypertension, such
as the SHEP, clinical trials in cardiovascular and renal dis-
ease have utilized diastolic or mean arterial pressure as
the parameter for titrating antihypertensive drugs. Future
studies should focus on control of systolic blood pressure
to reduce risk of hypertension complications, including
chronic kidney disease.
Proteinuria is recognized as an important risk factor
for progression of both diabetic and nondiabetic renal
disease [44–48]. In a small cohort of 77 patients with
hypertensive nephrosclerosis, we demonstrated that, as
compared to those with a urinary protein excretion
<500 mg/day, patients with a higher daily urinary pro-
tein excretion exhibited a significantly faster rate of de-
cline in GFR [44]. Similarly, patients with a urine protein/
creatinine ratio >0.22 enrolled in the African American
Study of Kidney Disease and Hypertension (AASK) ex-
hibited a twofold higher rate of decline in GFR as com-
pared with those with lower protein excretion rates [3].
Decreased glomerular filtration rate also has been as-
sociated with an increased risk for ESRD. In the AASK
trial, although blood pressure was controlled to levels as
low as 127/77 mm Hg, renal disease continued to progress
in patients (GFR level <40 mL/min/1.73 m2 and protein-
uria >300 mg/day) with hypertensive nephrosclerosis [3,
4, 44].
Dyslipidemia is a common finding in patients with
hypertensive nephrosclerosis. Several lines of evidence
implicate this as a risk factor for chronic kidney dis-
ease. In the ARIC study, hypertriglyceridemia and low
plasma levels of high-density lipoprotein (HDL) were
associated with the onset of hypertensive renal disease
[23]. Hypercholesterolemia was associated with the de-
velopment of ESRD in the MRFIT [10, 25]. In addition,
hypercholesterolemia correlates with global glomeru-
losclerosis in patients with biopsy-proven hypertensive
nephrosclerosis [49]. Moreover, LDL-cholesterol, small
dense LDL, and hypertriglyceridemia are associated with
renal disease progression [50, 51]. However, no clini-
cal trials have indicated that lipid-lowering therapy re-
duces the risk for onset or progression of hypertensive
nephrosclerosis. It therefore seems reasonable to use
current nationally accepted guidelines for lipid-lowering
therapy in hypertensive nephrosclerosis [52, 53].
Cigarette smoking has been associated with an in-
creased rate of decline in renal function in diabetics
and patients with hypertensive nephrosclerosis [54–57].
The mechanisms by which cigarette smoking likely con-
tributes to renal dysfunction have been reviewed else-
where [54].
Pathogenesis
The pathogenesis of hypertensive nephrosclerosis is
complex and incompletely understood. A genetic pre-
disposition to renal injury in the setting of hypertension
and reduced nephron number have been postulated as
important factors in the development and progression
of hypertensive nephrosclerosis. Indeed, animal studies
and human linkage analyses support the hypothesis that
a genetic susceptibility to renal disease exists in patients
with chronic renal disease. Rat models of hypertensive
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nephrosclerosis suggest that several genes predispose
the kidney to renal injury, and mouse models of lupus
nephritis indicate that genetic susceptibility is an im-
portant contributing factor to the development of re-
nal disease [30, 31, 58–65]. However, to date no gene or
group of genes has been linked to the development and
progression of hypertensive nephrosclerosis in humans.
Mapping of rat gene Rf-1 in humans has yielded vary-
ing success [64, 65]. A recent analysis indicated that a
region near a selected marker adjacent to the human
homologue of the Rf-1 gene contributes to ESRD sus-
ceptibility in African Americans [65]. It is likely that
multiple genes are involved in the predisposition to renal
injury in African Americans, and future studies have been
designed to identify such associations. Although candi-
date genes of the renin-angiotensin-aldosterone system
have been studied, the available data do not indicate a
strong likelihood that any of the components of this sys-
tem are pathogenetic in human hypertensive nephroscle-
rosis [66].
Several studies suggest that reduced nephron number
and nephron hypertrophy play a role in the development
of hypertension and the progression of renal disease [33–
37, 67], but this has not been shown to be a definitive cause
of kidney disease. Hypertension can cause renal vascular
injury, including ischemia and hypertrophy of glomeruli,
vessels, and tubules. Interstitial inflammation and fibrosis
are important components of the histopathologic lesions
observed in hypertensive nephrosclerosis and probably
derive in part from hypertensive injury [49]. Simultane-
ous afferent arteriolar vasoconstriction and vasodilation
involving different nephron populations might contribute
to hypertensive renal damage. Afferent vasoconstriction
might cause glomerular and tubular ischemia and lead
to glomerular simplification and thereby loss of filtration
surface area as well as tubular atrophy and tubulointer-
stitial inflammation/fibrosis, all histologic features com-
mon in hypertensive nephrosclerosis [49, 67]. In contrast,
afferent vasodilation in remnant nephrons of individu-
als with hypertension, especially those with low nephron
number, can cause glomerular hypertension and asso-
ciated glomerulosclerosis, proteinuria, and progressive
renal failure [32, 68–72].
Angiotensin II plays an important role in the progres-
sion of hypertensive nephrosclerosis. In animal models,
inhibition of angiotensin II synthesis or blockade of the
angiotensin type-1 receptor reduces blood pressure, renal
injury, proteinuria, and progression of kidney disease [3,
4, 68, 72–76]. In humans with hypertensive nephroscle-
rosis, lowering blood pressure with an ACE inhibitor
reduces proteinuria and preserves renal function [3, 47,
74–77]. Taken together, these data strongly support a crit-
ical role for angiotensin II in the progression of hyperten-
sive nephrosclerosis.
Table 2. Pathologic lesions in hypertensive nephrosclerosis
Arteriosclerosis and arteriolosclerosis
Medial hypertrophy
Intimal fibrosis
Hyalinosis
Global glomerulosclerosis
Segmental glomerulosclerosis
Tubulointerstitial changes
Tubular atrophy
Inflammation
Fibrosis
Diagnosis
The definition of hypertensive nephrosclerosis is not
based on rigorously developed criteria [66]. I have
defined hypertensive nephrosclerosis as nondiabetic
chronic kidney disease associated with chronic (often
stage 3) hypertension, with or without moderate pro-
teinuria, and a pathologic picture characterized by ar-
teriosclerosis, arteriolosclerosis, glomerulosclerosis, and
interstitial fibrosis in the absence of immune deposits. It
is important to recognize that, like diabetic nephropathy
and in contrast to various glomerulonephritides, the diag-
nosis of hypertensive nephrosclerosis is generally based
on clinical criteria, not renal biopsy criteria. The reason
is that very few individuals with chronic renal disease
or ESRD attributed to hypertension, that is, hyperten-
sive nephrosclerosis, undergo a renal biopsy. Therefore,
the diagnosis of hypertensive nephrosclerosis is almost
always based on history, physical examination, urinaly-
sis, and serologic testing. Indeed, the major reason for
pathologic identification of hypertensive nephrosclerosis
is that clinicians perform a renal biopsy based on clinical
suspicion of glomerulonephritis because of proteinuria
[66, 75]. It is important to note, however, that clinical
criteria can be strongly associated with the histopatho-
logic lesion of hypertensive nephrosclerosis [49, 75]. In
patients undergoing renal biopsy for research purposes,
nondiabetic hypertensive African Americans with mild
to moderate renal insufficiency in the absence of marked
proteinuria were overwhelmingly likely to have renal
vascular lesions consistent with the clinical diagnosis of
hypertensive nephrosclerosis [49] (Table 2). Thus,
middle-aged African Americans with longstanding mod-
erate to severe hypertension, stage 3 chronic kidney dis-
ease (GFR < 60 mL/min), and urine protein/creatinine
ratio < 2.5 are likely to exhibit renal pathology con-
sistent with hypertensive nephrosclerosis. Nevertheless,
unselected patients with a clinical diagnosis of hyperten-
sion are frequently discovered to have a renal disease
other than hypertensive nephrosclerosis [75]. In African
Americans with hypertensive nephrosclerosis, solidified
global glomerulosclerosis is more common than in white
patients with hypertensive nephrosclerosis [78]. Despite
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the fact that hypertension is identified as the cause of
ESRD in almost 30% of incident patients in the United
States today, a vanishingly small number of these cases
have had this diagnosis confirmed by renal biopsy. This is
important because (1) an overestimation of hypertensive
nephrosclerosis and, hence, an underestimation of other
renal diseases is possible, and (2) no rigorous criteria exist
for the diagnosis of hypertensive nephrosclerosis, includ-
ing histologic criteria. It is clear that a better definition for
the phenotype of hypertensive nephrosclerosis is needed.
Rate of progression of kidney disease
The rate of progression of hypertensive nephrosclero-
sis is relatively slow. The rate of decline in GFR is similar
in diabetic nephropathy and polycystic kidney disease,
5–6 mL/min/year [45–48]; the rate in proteinuric pa-
tients with nondiabetic nephropathies is the highest,
6–8 mL/min/year [47]. Among common renal diseases,
treated hypertensive nephrosclerosis has the slowest av-
erage rate of decline in glomerular filtration rate, 1–2 mL/
min/year [4, 44]. Figure 2 illustrates the impact of this
rate of decline on a hypothetical patient with treated
hypertensive nephrosclerosis. As shown in the figure, a
50-year-old man with a baseline GFR of 50 mL/min would
develop ESRD requiring dialysis in 20 years, or at age 70.
Interventions that reduce this rate of progression might
prevent ESRD and the need for dialysis.
Treatment
Clinical trials of management of hypertensive
nephrosclerosis are few. Only the AASK prospectively
examined the impact of clinical management on renal
outcomes in patients with hypertensive nephrosclero-
sis. Previous large-scale clinical trials in hypertensive pa-
tients designed to examine the impact of blood-pressure-
lowering on cardiovascular disease [1, 8, 79–83] had only
a few renal events. The HDFP demonstrated that the like-
lihood of deterioration in renal function was higher in the
patients whose blood pressure was less strictly controlled
[1]. Ad hoc analyses of the MRFIT demonstrated that the
likelihood of deterioration in renal function was greater
in African Americans despite similar blood pressure con-
trol as in whites [8, 79]. Clinical management studies con-
sisting of mixed chronic kidney disease populations also
demonstrated that stricter blood pressure control was as-
sociated with a reduced likelihood of progression of re-
nal disease [40, 84, 85]. In a long-term follow-up study
of hypertensive patients, Perry et al demonstrated that
in patients with a decrease in systolic blood pressure by
more than 20 mm Hg, the rate of ESRD was decreased
by nearly two-thirds [40]. These data were suggestive but
not conclusive that blood-pressure-lowering in hyperten-
sive patients reduces the likelihood of ESRD. However,
none of these studies specifically focused on hypertensive
nephrosclerosis with established chronic kidney disease,
and the multicenter trials were not designed to examine
renal outcomes.
We previously reported the results of a single-center
trial involving 77 patients with hypertensive nephroscle-
rosis that was specifically designed to examine the impact
of blood-pressure-lowering on the rate of decline in GFR
estimated by renal clearance of iothalamate [44]. In our
study, hypertensives with a GFR <70 mL/min (range 15–
70 mL/min) were randomly assigned to one of two blood
pressure groups: strict control or diastolic blood pressure
<80 mm Hg, and conventional control or diastolic blood
pressure of 85–90 mm Hg. All participants entered into
the trial had their blood pressure lowered to <80 mm
Hg prior to randomization. Participants were followed
for about 40 months; decline in GFR was the primary
outcome. We found that the average rate of decline in
both groups was not significantly different from zero and
there was no difference between groups despite a sig-
nificant 6 mm Hg difference in achieved diastolic blood
pressure. There were 7 of 42 and 2 of 35 cases of ESRD
in the strict and conventional blood pressure groups,
respectively, rates that were not significantly different.
Rates of decline in GFR among African Americans and
non-African Americans were not significantly different
despite significantly higher achieved diastolic blood pres-
sures in African Americans. This study provided strong
and convincing evidence that long-term lowering of blood
pressure in high-risk patients (mostly African American
males) with moderate to severe hypertension, hyperten-
sive nephrosclerosis, and GFR of 30–60 mL/min is associ-
ated with a very slow average rate of decline in GFR, not
different from that of aging. Moreover, the data suggested
that lowering blood pressure in African Americans to a
similar degree as in whites was not associated with a more
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Table 3. African American Study of Kidney Disease and
Hypertension (AASK) study design: Randomization scheme
Drug classa
Metoprolol Amlodipine Ramipril
Usual blood pressure goal 20% 10% 20%
Lower blood pressure goal 20% 10% 20%
Combined number 441 217 436
a Percentage represents proportion of study cohort randomized to indicated
study group. For example, 10% of the cohort was randomized to the usual blood
pressure goal and amlodipine.
rapid decline in renal function. However, this small trial
did not show different rates of decline at lower blood
pressure and was not designed to examine the effect of
different antihypertensive agents on outcome.
The AASK trial was designed to answer two impor-
tant questions. Does aggressive lowering of blood pres-
sure result in slower decline in renal function? Does the
type of antihypertensive agent used to lower blood pres-
sure affect renal outcomes [86]? The study was a prospec-
tive, randomized, double-blind controlled trial utilizing
a 2 × 3 factorial design (Table 3). Nondiabetic African
Americans age 18 to 70 years with a clinical diagnosis of
hypertensive nephrosclerosis, a diastolic blood pressure
≥95 mm Hg, GFR in the range of 20–65 mL/min/1.73 m2,
and a urine protein/creatinine ratio <2.0 were enrolled
in the trial. They were randomized to one of two
levels of blood pressure control and one of the following:
metoprolol (control group), ramipril, or amlodipine. Ad-
ditional antihypertensive agents were added to achieve
blood pressure goals; patients were followed for up to
5 years (mean follow-up, 3.4 years). The primary out-
come was the rate of decline in GFR, and the secondary
outcome was a composite of a rapid decline in GFR
(50% reduction or 25 mL/min absolute reduction from
baseline), ESRD, or death from any cause. The results
of the blood pressure comparison groups revealed no
significant difference between the lower blood pressure
and the usual blood pressure group in the rate of de-
cline in GFR or in the secondary composite outcome. It
is important to note that achieved mean arterial blood
pressure was about 10 mm Hg lower in the lower blood
pressure group as compared to the usual blood pressure
group. This difference was achieved within 6 months and
was maintained throughout follow-up. Not even a slight
trend suggested that lower blood pressure improved re-
nal outcome. However, a significantly greater increase in
proteinuria persisted throughout the study in the usual
blood pressure as compared to the lower blood pressure
group. Furthermore, for patients with a baseline protein-
uria <300 mg/day, assignment to the lower blood pres-
sure group was associated with reduced risk for devel-
opment of proteinuria >300 mg/day. Whether this dif-
ference in proteinuria indicated long-term renal pro-
tection for the lower blood pressure group cannot be
ascertained from the AASK study. Despite these neg-
ative results in the blood pressure comparisons, the out-
comes among the drug group assignments revealed im-
portant differences. Overall, there were no differences
in the rate of decline in GFR among the drug treat-
ment groups. This was in part due to the fact that in
the amlodipine group, there was a sharp and signifi-
cant increase in GFR during the first 6 months of the
trial, as compared to the metoprolol control group and
the ramipril group. In contrast, the cumulative event
rate for the composite outcome of rapidly declining
GFR, ESRD, or death was significantly lower in the
ramipril as compared either with the metoprolol or the
amlodipine groups. There was a 22% risk reduction
(P < 0.042) for ramipril compared to metoprolol, and
38% for ramipril compared with amlodipine (P = 0.004).
No difference appeared between the amlodipine and
metoprolol groups for the composite outcome. However,
for the combined outcome of ESRD and death, treatment
with ramipril, as compared to amlodipine, was associated
with a 49% risk reduction (P < 0.01), and treatment with
metoprolol, as compared to amlodipine, was associated
with a 42% risk reduction (P = 0.003).
Proteinuria is an important risk factor for progression
of hypertensive nephrosclerosis and is generally associ-
ated with a lower GFR [4, 43, 74, 86]. The AASK trial
found a significant interaction between baseline protein-
uria and outcomes for both blood pressure control level
and drug groups with respect to GFR decline and com-
posite clinical outcome. Baseline proteinuria was a strong
predictor of progression of renal disease, and patients
with higher proteinuria also had lower baseline GFR. Pa-
tients with baseline protein excretion rate >300 mg/day
or a urine protein/creatinine ratio of >0.22 had a rate of
decline in GFR of approximately 5 mL/min/year as com-
pared to 2 mL/min/year in those with a baseline urine
protein/creatinine ratio <0.22. Moreover, the composite
clinical end point event rate was nearly 5 times higher
in patients with proteinuria at baseline (>300 mg/day)
versus nonproteinuric participants. The rate of decline in
GFR from entry to completion of follow-up was faster
in the proteinuric subgroup. Also, subgroup analysis in-
dicated that both ramipril and metoprolol were associ-
ated with a lower composite event rate as compared to
amlodipine-treated participants. The results of these and
other analyses from this landmark clinical trial likely will
provide new insights and directions for future research
into hypertensive nephrosclerosis.
QUESTIONS AND ANSWERS
Dr. John T. Harrington (Division of Nephrology, Tufts-
New England Medical Center, Boston, Massachusetts):
Bob, that was a superb review of the complicated
pathogenesis of hypertensive nephrosclerosis in African
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Americans. One of the problems I’ve always had with
hypertension and progressive kidney failure is the
chicken and egg phenomenon. In a recent article in the
New England Journal of Medicine, Ritz’s group com-
pared glomerular counts in kidneys from 10 control
patients with counts in kidneys from patients with hyper-
tension [35]. In round numbers, the glomerular counts
were 700,000 in the hypertensive group and 1.4 million
in the control group. Which comes first? Does hyperten-
sion cause the low glomerular count or vice versa? Could
you comment on a general level, and specifically on Ritz’s
data?
Dr. Toto: First of all, I agree with you. I’ve been work-
ing on this problem for about 20 years. I think the chicken
and the egg issue is still open. I don’t think that the obser-
vation of Ritz’s group changes that, but it’s an important
observation. As I pointed out, several studies indicate
that nephron number might be lower in certain groups.
African Americans have been suggested as one of those
groups—maybe they have smaller kidneys, a smaller
number of nephrons, more hypertrophic nephrons—and
some data have compared blacks to whites, although the
studies were limited in scope. In preparation for this Fo-
rum, I was amazed to find that in the past 10 to 15 years we
still haven’t gotten a clear answer about what this disease
process is. What you are asking is whether the kidney
is being damaged by the hypertension. Maybe African
American patients with kidney failure have an intrinsic
renal disease causing their hypertension. Biopsy of the
kidney with current techniques that we use to character-
ize the disease is not enough to help make that distinction.
Dr. Harrington: My second question is an epidemio-
logic one. You looked at studies comparing blacks and
whites in the United States. Have comparable studies
been carried out in other parts of the world, specifically in
Africa or the Caribbean? What, if anything, can we learn
from such studies?
Dr. Toto: I’m not aware of any other countries that have
looked at this carefully as in the USRDS. South Africa
would be the place that one most likely would look. In
Australia, Dr. Wendy Hoy looked at differences in abo-
riginal populations and found a higher incidence of renal
failure and ESRD associated with hypertension than in
nonaboriginal populations [14]. Dr. Hoy has been char-
acterizing these data epidemiologically and her findings
are consistent with the United States data.
Dr. Angelo A. Ucci, Jr. (Division of Pathology, Tufts-
New England Medical Center): I was interested in your
pointing out that the pathologic changes are general ones.
They mostly characterize injury to various parts of the
renal structures. Do you have a sense about what would
make a better diagnostic group of criteria for this disease?
A combination of both clinical and pathologic, or new
approaches?
Dr. Toto: I think we need better criteria. I think we’re
going to find better histologic markers that will help us
differentiate changes. We might discover histologic or his-
tochemical techniques that uncover endothelial markers
or genetic markers in the kidney in these patients. I could
only guess at what specific proteins we should look at.
Clearly we need better tools to provide diagnostic clarity
and specificity to hypertensive patients with chronic re-
nal disease. Perhaps we should perform kidney biopsies
in more hypertensive patients.
You might have seen the article from Dr. Fogo’s group
that came out in Kidney International last year in which
they compared the histopathology in white patients with
that in blacks [78]. They did find some differences, how-
ever, as they noted, selection bias might have played a
role insofar as it was a retrospective analysis. In their
analysis, African Americans had worse renal function at
the time of biopsy; that is, their creatinines were 4.0 to 5.0
mg/dL, whereas in whites, creatinine ranged from 2.5 to
3.0 mg/dL. The serum creatinine level is expected to be
slightly higher in the African Americans than in the non-
African Americans; still, the study could have biopsied
some patients at a later stage of (more severe) disease.
So the disease looks more severe, but is it really differ-
ent? If we don’t have a marker better than a renal biopsy,
perhaps we should do more. The downside is that it might
not make a difference therapeutically today. But until we
have noninvasive markers, perhaps we should consider a
carefully designed study to evaluate renal biopsy to move
this field forward. In most cases, we lower the blood pres-
sure, give an ACE inhibitor, and follow the serum creati-
nine level.
Dr. Dana Miskulin (Division of Nephrology, Tufts-New
England Medical Center): I wonder whether body mass
index, that is, obesity, was independently associated with
a faster progression of hypertensive nephrosclerosis in
the AASK study.
Dr. Toto: I’m not aware of any convincing epidemi-
ologic data. I’ve seen some data that suggest that over-
weight might be a risk factor for renal disease. I don’t
know that there’s any hard data on that–maybe someone
in the audience can comment on that. I’m not aware of
any studies that have clearly demonstrated that obesity,
per se, is a risk factor.
Dr. Miskulin: I also want to ask about the effect of
blood pressure control on renal progression. Did the ef-
fect of the low blood pressure intervention vary across
subgroups with different baseline levels of kidney func-
tion? For example, one might hypothesize that no effect
or even a detrimental effect was found for individuals
with relatively advanced disease (GFR ∼ 20 mL/min/
1.73 m2), whereas beneficial effects might be found in
those with relatively preserved kidney function (GFR >
45 mL/min/1.73 m2).
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Dr. Toto: I have a couple of comments. First, that
is a subgroup analysis so you have to be careful about
that. This wasn’t a prespecified analysis, as I remember.
Second, this was one of the issues that we grappled with
during the design of AASK. Shouldn’t we start earlier,
for example, select patients with a GFR of 80 and follow
them long-term? The downside is this: the disease gener-
ally progresses slowly, so if you take patients into the trial,
most of whom have a decline in GFR of 2 mL/min/year,
you have to follow them a very long time. Then what?
Should you look at an alternative surrogate outcome or
continue to follow GFR?
Dr. Mark Sarnak (Division of Nephrology, Tufts-New
England Medical Center): You presented results demon-
strating that tight blood pressure control did not slow the
progression of GFR decline in the AASK study. What is
your recommendation to patients regarding target blood
pressure? My concern is that most patients with chronic
kidney disease die from cardiovascular disease rather
than develop end-stage renal disease, and therefore tar-
get blood pressure needs to take both risks into account.
A related question is whether the follow-up cohort com-
ponent of the AASK study will have sufficient power to
evaluate risk factors for cardiovascular outcomes.
Dr. Toto: You’re making an excellent point, namely,
that there’s “competition” between death or disability
from cardiovascular disease and progression of renal dis-
ease to end stage. As you know, recent data suggest that
people who have a myocardial infarction or stroke might
have a higher likelihood of developing renal failure. To
answer specifically the issue about the decline in GFR, we
are rethinking whether that’s the best way to follow pa-
tients with kidney disease. There is a lot of debate about
what should be the right renal outcome to measure and
what size clinical trial will be required to define statis-
tically the number of cardiovascular events. My current
recommendation is to achieve and maintain blood pres-
sure in the range of 130–140/75–85 mm Hg in hyperten-
sive nephrosclerosis. The AASK cohort study is track-
ing cardiovascular disease events and cardiovascular out-
comes, including hospitalizations and deaths from any
cause, including cardiovascular death. More than 700 pa-
tients are being followed currently. The cohort will have
adequate power for us to evaluate risk factors.
Dr. Jeanine Carlson (Division of Nephrology, Tufts-
New England Medical Center): It would appear that once
an African American patient has developed hypertensive
nephrosclerosis to any degree, the natural history is for
it to progress to ESRD despite the adequacy of blood
pressure control. If we consider your schematic, where
you postulate the progression of this disease (Fig. 2), per-
haps we are not identifying patients at risk early enough.
Do you think we should be using a stricter definition of
hypertension in the African American population, per-
haps beginning antihypertensive therapy when the blood
pressure is greater than 130/80 mm Hg rather than waiting
until it is 140/90 mm Hg?
Dr. Toto: Yes, but this is a personal bias on my part.
Remember, the AASK study doesn’t show any renal ben-
efit of lower blood pressure comparing 140/85 mm Hg to
127/77 mm Hg. You might ask, “Why would you lower
the blood pressure to any more than 140/85 mm Hg?”
You might need to add more blood pressure medicines
to achieve a lower level of blood pressure but the patient
still remains at higher risk for a stroke or myocardial in-
farction. The cardiovascular event rate in AASK was too
low to show a difference between the two levels of blood
pressure compared. Specifically, if I don’t start treating
a patient’s blood pressure earlier than we currently do,
perhaps damage is already ongoing and irreversible. We
do not know this, but we need to find out whether it is
true.
Dr. Ronald Perrone (Division of Nephrology, Tufts-
New England Medical Center): How would you integrate
the results of the ALLHAT trial with the AASK trial?
My understanding is that the African Americans in the
ALLHAT study perhaps did worse on ACE inhibitors in
terms of blood pressure control.
Dr. Toto: The ALLHAT population is considerably dif-
ferent than the AASK study population. Most of the pa-
tients in the AASK study were already taking several
antihypertensive medications when they came in. Most
of the patients in the AASK trial could not have their
blood pressure controlled with a thiazide diuretic or one
other agent. As I said earlier, many AASK study patients
didn’t have much of a response to hydrochlorothiazide
and needed additional agents. As far as doing worse, our
AASK data show that when you give an ACE inhibitor
in the context of “adequate” blood pressure control in
this patient population, it is more protective than a beta
blocker or calcium channel blocker. Obviously, giving an
ACE inhibitor is not enough. We did two things. We
blocked ACE and lowered the blood pressure substan-
tially in these patients. Maybe the ACE inhibitor is the
better antihypertensive agent when used in conjunction
with these other drugs. In HOPE study participants who
had undergone ambulatory blood pressure measurement,
ramipril, given at night, caused a 10 mm Hg reduction in
nocturnal blood pressure compared to the placebo group.
Dr. Perrone: In a 30-year-old hypertensive African
American with a creatinine of 1.2 mg/dL and a blood
pressure of 140/90 mm Hg, what would be your drug of
choice?
Dr. Toto: I would like to know whether the patient has
an abnormal urinalysis and especially whether protein-
uria is present. My approach would be to use an ACE
inhibitor if proteinuria is present. The ALLHAT study
would suggest using a thiazide in a patient with a creati-
nine of 1.2 mg/dL, and that might be fine as long as the
blood pressure is controlled to 130 mm Hg systolic.
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Dr. V. S. Balakrishnan (Division of Nephrology,
Tufts-New England Medical Center): Getting back to
pathogenesis, could you speculate on the role of trans-
forming growth factor-b1 (TGF-b1) or plasminogen acti-
vator inhibitor-1 (PAI-1) in this disease, especially in light
of the recent polymorphisms that have been identified in
their genes?
Dr. Toto: That’s an excellent question. As you know,
plasma levels of TGF-b are higher in some African Amer-
icans than in whites in some studies. Cytokines are impor-
tant in the development of fibrosis of the blood vessels
and in the kidneys of these patients. I’m not sure that
variations in the genes that are controlling the specific
cytokine are really going to be important in the patho-
genesis of hypertensive nephrosclerosis. We are finding
more and more cytokines and that makes it very diffi-
cult to select one or two as the critical cytokine. If you
did have to pick one gene, I’d speculate that it is the
gene for angiotensin II. One can think of angiotensin
II as a cytokine because it has so many nonhemody-
namic effects, as well as its better-known hemodynamic
effects.
Dr. Harrington: Let me ask a hypothetical question.
If you were advising the director of the NIH on clinical
trials in nephrology and you’re allowed only $60 million
for two trials, what two studies would you choose?
Dr. Toto: I would probably spend my money on one
study because they’re getting so expensive now. I would
look at cardiovascular disease outcomes in a chronic renal
disease population. I would spend the money on either
hypertension or diabetes, or common diseases that we
see that account for this huge disease burden and the
associated health care cost. I would do a longer study with
a larger number of patients without a lot of measures of
GFR that would cost me a lot of my budget.
If I were going to perform two studies, then I would do
one study in the pre-ESRD chronic renal disease popu-
lation and the other in the dialysis population using the
end point of all-cause mortality. I would try to reconstruct
something like the statin trial using a drug that you could
give to most patients, and I would make inclusion criteria
relatively simple. I would try to think outside the box in
terms of clinical trials. Instead of measuring GFR, which
is terribly expensive, difficult to interpret, and variable,
I would try to imitate the HOPE trial in a renal pop-
ulation. That is, I like the idea of taking 2000 or 3000
dialysis patients and giving one-half of them a statin and
the other half placebo or vitamin E and seeing whether
we can reduce morbidity and mortality. The best example
that I can think of is the SPACE trial from Israel in which
patients given vitamin E, 800 units, showed a reduction
in secondary cardiovascular events [87]. That study des-
perately needs to be confirmed. Vitamin E is relatively
inexpensive and it’s safe.
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